Targeting AURKA by CRISPR/SaCas9 Alters Cell Cycle Progression and Enhances Lenvatinib-Associated Reduction in Cell Viability in Hepatocellular Carcinoma: An Integrated In Silico and HepG2 in Vitro Study

Hepatocellular carcinoma (HCC) presents substantial clinical concerns as a result of its high treatment resistance, frequent recurrence, and strong correlation with chronic liver diseases. Aurora kinase A (AURKA) is overexpressed in HCC correlating with poor prognosis and treatment resistance. Our bioinformatics analyses revealed that AURKA overexpression in HCC is associated with mitotic proteins and oncogenes, emphasizing its role in cancer progression. CRISPR/SaCas9-mediated AURKA knockdown markedly reduced AURKA expression levels through inducing several indels in the AURKA gene sequence, resulting in functional consequences including upregulation of p21, p53, and caspase-8, as well as downregulation of CDK1, CDK2, PI3K (alpha subunit), P38, and BCL-2 genes. Flow cytometry verified that these alterations were compatible with G2-phase cell cycle arrest and slight activation of apoptosis. Also, scratch and colony formation assays indicated a significant reduction in metastatic and proliferative potential. Furthermore, AURKA knockdown combined with Lenvatinib significantly reduce HepG2 cell viability compared with either treatment alone. Mechanistically, this study indicated that AURKA suppression reduced cell viability/proliferation by the modulation of oncogenic PI3K/AKT and p38/MAPK pathways. These in-silico and in-vitro findings highlight the critical role of AURKA in HCC pathogenesis. Here, the CRISPR/SaCas9-mediated genetic disruption of AURKA reveals its mechanistic role in regulating cell cycle, apoptosis, and tumor-suppressor signalling. Our study demonstrates AURKA as a potential molecular target to suppress HCC, while providing genetic evidence that its downregulation enhances Lenvatinib effect.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-18
DOI
https://doi.org/10.64898/2026.11.17.767223
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Targeting AURKA by CRISPR/SaCas9 Alters Cell Cycle Progression and Enhances Lenvatinib-Associated Reduction in Cell Viability in Hepatocellular Carcinoma: An Integrated In Silico and HepG2 in Vitro Study

E. Mahmoud, Rania Hassan Mohamed, Mahmoud ElHefnawi, Noha Samir Taibe et al.
bioRxiv (Cold Spring Harbor Laboratory)
Hepatocellular Carcinoma Treatment and Prognosis
preprint

Targeting AURKA by CRISPR/SaCas9 Alters Cell Cycle Progression and Enhances Lenvatinib-Associated Reduction in Cell Viability in Hepatocellular Carcinoma: An Integrated In Silico and HepG2 in Vitro Study

E. Mahmoud, Rania Hassan Mohamed, Mahmoud ElHefnawi, Noha Samir Taibe, Bangly Soliman
preprint en

Abstract

Hepatocellular carcinoma (HCC) presents substantial clinical concerns as a result of its high treatment resistance, frequent recurrence, and strong correlation with chronic liver diseases. Aurora kinase A (AURKA) is overexpressed in HCC correlating with poor prognosis and treatment resistance. Our bioinformatics analyses revealed that AURKA overexpression in HCC is associated with mitotic proteins and oncogenes, emphasizing its role in cancer progression. CRISPR/SaCas9-mediated AURKA knockdown markedly reduced AURKA expression levels through inducing several indels in the AURKA gene sequence, resulting in functional consequences including upregulation of p21, p53, and caspase-8, as well as downregulation of CDK1, CDK2, PI3K (alpha subunit), P38, and BCL-2 genes. Flow cytometry verified that these alterations were compatible with G2-phase cell cycle arrest and slight activation of apoptosis. Also, scratch and colony formation assays indicated a significant reduction in metastatic and proliferative potential. Furthermore, AURKA knockdown combined with Lenvatinib significantly reduce HepG2 cell viability compared with either treatment alone. Mechanistically, this study indicated that AURKA suppression reduced cell viability/proliferation by the modulation of oncogenic PI3K/AKT and p38/MAPK pathways. These in-silico and in-vitro findings highlight the critical role of AURKA in HCC pathogenesis. Here, the CRISPR/SaCas9-mediated genetic disruption of AURKA reveals its mechanistic role in regulating cell cycle, apoptosis, and tumor-suppressor signalling. Our study demonstrates AURKA as a potential molecular target to suppress HCC, while providing genetic evidence that its downregulation enhances Lenvatinib effect.

bioRxiv (Cold Spring Harbor Laboratory)
Ain Shams University (EG), Cairo University (EG), National Research Centre (EG)
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon